Phase II study of MS 275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma

Trial Profile

Phase II study of MS 275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Entinostat (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 22 Jan 2009 Actual end date and trial identifier (91410) added from ClinicalTrials.gov.
    • 01 Aug 2008 Results published in Melanoma Research.
    • 04 Dec 2006 The expected completion date for this trial is now 1 Nov 2006.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top